DR. LAL PATH LABS LTD.
Latest filings
Next results: Wed, 4 Nov · Financial Results- Dr. Lal PathLabs to discuss Q2 and H1 FY27 results on November 4 · Board & Shareholder Meetings
- Board to consider second interim dividend for FY2026-27 · Corporate Actions
- Board to review September results and consider second interim dividend · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates a diagnostic testing network with central laboratories and patient collection centres across India. In FY26, it added 14 new labs and over 1,100 collection centres, taking the network wider; revenue for the year was Rs. 2,763 crore, up 12.2% year-on-year. Around 75% of revenue comes from B2C patients and the balance from B2B referrals (doctors, hospitals and institutions). The Swasthfit preventive-health package brand contributed 27% of FY26 revenue, while Sovaaka — an AI-powered premium wellness screening brand — was launched with one centre in January 2026. Tier 3+ cities now account for 39% of revenue, and the company is expanding internationally through a Dubai subsidiary and an 80% stake in Ghana's Sunshine Healthcare. The largest cost line is materials (reagents and consumables) at 19.3% of revenue, followed by employee costs at 18.2% and other operating expenses at 34.1%.
Scorecard
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from DR. LAL PATH LABS LTD.'s filed financials and exchange disclosures
What does DR. LAL PATH LABS LTD. do?
DR. LAL PATH LABS LTD. is a Healthcare Services company listed on NSE and BSE, trading under the symbol LALPATHLAB.
Is DR. LAL PATH LABS LTD. profitable?
Yes. Over the trailing twelve months DR. LAL PATH LABS LTD. reported a net profit of ₹546 Cr on revenue of ₹2,891 Cr.
Does DR. LAL PATH LABS LTD. pay a dividend?
Yes. The dividend yield is 0.69% at the current price. It paid out 44% of its profit as dividend in FY26.
Is DR. LAL PATH LABS LTD. debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹243 Cr of cash.
Is DR. LAL PATH LABS LTD. expensive compared with its peers?
On trailing P/E, DR. LAL PATH LABS LTD. ranks 17 of 25 in Healthcare Service Provider — cheaper than 33% of them, against an industry median of 23.4×. This is a position, not a valuation judgement.
How much does the DR. LAL PATH LABS LTD. share price move in a day?
On a typical session DR. LAL PATH LABS LTD. moves 1.06% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are DR. LAL PATH LABS LTD.'s next results?
Financial Results on Wed, 4 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track DR. LAL PATH LABS LTD.'s announcements?
Every NSE and BSE filing by DR. LAL PATH LABS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.